Search papers, labs, and topics across Lattice.
Site4Drug is an AI-driven agent designed to identify and rank targetable sites on membrane proteins, addressing the complexities of accessibility and post-translational modifications that complicate drug design. By integrating various modalities and providing detailed evidence summaries and risk flags, it enables users to make informed decisions without pre-specifying drug modalities. The core finding reveals that Site4Drug effectively recommends binding modalities based on the same evidence used for site discovery, enhancing the accuracy of target selection in drug development.
Site4Drug revolutionizes drug target selection by autonomously recommending binding modalities based on comprehensive evidence, minimizing the risk of biologically occluded sites.
Selecting where to intervene on a protein (i.e., choosing a targetable site) is often a more ambiguous and failure-prone bottleneck than selecting what binds, especially for membrane proteins where accessibility, topology, and post-translational modifications (PTMs) constrain actionable regions. We present Site4Drug, a modality-aware site-finding agent that outputs a ranked list of targetable regions with explicit constraints, evidence summaries, risk flags, and a traceable decision log. Rather than requiring users to specify the drug modality upfront, Site4Drug can recommend a binding modality (e.g., antibody/peptide-like vs small-molecule) from the same evidence used for site discovery, including topology, hydropathy, PTM propensity, disulfides, domain context, and sequence. Importantly, this evidence is applied consistently across modalities, including small-molecule pocket discovery, to avoid selecting chemically plausible but biologically occluded sites.
BAIR